{
    "clinical_study": {
        "@rank": "53742", 
        "arm_group": [
            {
                "arm_group_label": "4 mg/kg Onartuzumab (MetMAb)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "15 mg/kg Onartuzumab (MetMAb)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "30 mg/kg Onartuzumab (MetMAb)", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This phase I study will examine the pharmacokinetics and safety of Onartuzumab (MetMAb) in\n      chinese patients with locally advanced or metastatic solid tumors. Patients will be divided\n      into 3 cohorts, which will each be given a different dose of MetMAb. The cohorts will be\n      treated sequentially, starting with the lowest dose. MetMAb will be administered\n      intravenously every 3 weeks. Patients may be treated for up to 16 cycles (21 days each) or 1\n      year, whichever occurs first, in the absence of disease progression."
        }, 
        "brief_title": "The Pharmacokinetics and Safety of Onartuzumab (MetMAb) in Chinese Patients With Locally Advanced or Metastatic Solid Tumors", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Neoplasms", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age >/= 18 years\n\n          -  Histologically confirmed locally advanced or metastatic solid tumor that does not\n             respond to standard treatment or for which there is no further standard treatment.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status from 0 to 2.\n\n          -  Use of effective contraception\n\n          -  Life expectancy > 3 months\n\n        Exclusion Criteria:\n\n          -  Brain metastasis or spinal cord compression that has not yet been definitively\n             treated with surgery and/or radiation, and/or patients with brain metastasis that\n             have been receiving corticosteroids.\n\n          -  Previously diagnosed and treated central nervous system (CNS) metastases or spinal\n             cord compression that has not been clinically stable for at least 2 months.\n\n          -  Treatment with anti-tumor therapy within 4 weeks before the start of study treatment,\n             with the following exception: Patients with metastatic prostate cancer on maintenance\n             hormonal therapy, provided they meet all other eligibility criteria.\n\n          -  Current, serious or uncontrolled, systemic illness.\n\n          -  Recent stroke (within the past 6 months).\n\n          -  Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory\n             drugs (NSAIDs).\n\n          -  History of cardiovascular conditions.\n\n          -  Any other disease, gastrointestinal abnormality, metabolic dysfunction, physical\n             examination finding, or clinical laboratory finding giving reasonable suspicion of a\n             disease or condition that contraindicates the use of an investigational drug or that\n             may affect the interpretation of the results or render the patient at high risk from\n             treatment complications.\n\n          -  Receipt of any investigational agent, or participation in any other clinical study,\n             within 4 weeks before the start of study treatment.\n\n          -  Major surgery within 4 weeks before the start of study treatment, without complete\n             recovery.\n\n          -  Significant traumatic injury within 3 weeks before the start of study treatment (All\n             wounds must be fully healed prior to Day 1).\n\n          -  Uncontrolled excess calcium levels.\n\n          -  Known human immunodeficiency virus (HIV) infection.\n\n          -  Inadequate organ function\n\n          -  Pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02031731", 
            "org_study_id": "YO28211"
        }, 
        "intervention": [
            {
                "arm_group_label": "4 mg/kg Onartuzumab (MetMAb)", 
                "description": "4 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.", 
                "intervention_name": "4 mg/kg Onartuzumab (MetMAb)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "15 mg/kg Onartuzumab (MetMAb)", 
                "description": "15 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.", 
                "intervention_name": "15 mg/kg Onartuzumab (MetMAb)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "30 mg/kg Onartuzumab (MetMAb)", 
                "description": "30 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.", 
                "intervention_name": "30 mg/kg Onartuzumab (MetMAb)", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 8, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100142"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changchun", 
                        "country": "China", 
                        "zip": "130021"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "zip": "510060"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "A PHASE I STUDY OF THE PHARMACOKINETICS AND SAFETY OF ONARTUZUMAB IN CHINESE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: YO28211 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "measure": "Total exposure of MetMAb, as measured by area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02031731"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Incidence of anti-therapeutic antibodies against MetMAb", 
            "safety_issue": "No", 
            "time_frame": "Up to 1 year"
        }, 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}